Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787961 | 0.76 | FDPS (0.47) | FDPSLTA4HALDH1A1TSHRNOS1 | |
| SCHEMBL2749419 | 0.69 | L3MBTL1 (0.44) | ALDH1A1SLC6A3ALOX15 | |
| SCHEMBL8447530 | 0.68 | CYP2C9 (0.45) | LTA4HALDH1A1TSHRSLC6A3CYP2C19 | |
| SCHEMBL243565 | 0.68 | — | — | |
| SCHEMBL28864121 | 0.67 | KDM4C (0.36) | FDPSALDH1A1KDM4CPKM | |
| SCHEMBL5785411 | 0.67 | LTA4H (0.38) | FDPSLTA4HALDH1A1TSHRNOS1 | |
| SCHEMBL8671012 | 0.67 | FDPS (0.47) | FDPSALDH1A1TSHRNOS1HSD17B10 | |
| SCHEMBL243566 | 0.65 | — | — | |
| SCHEMBL378027 | 0.64 | PDPK1 (0.50) | LTA4HALDH1A1SLC6A3 | |
| SCHEMBL6163997 | 0.64 | CYP17A1 (0.50) | FDPSLTA4HALDH1A1HSD17B10SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192708-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-22 | — | — | US | disclosed |
| US-11608341-B2 | Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2023-03-21 | — | — | US | disclosed |
| US-20200369672-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369672-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | C3AR1, C5AR1, C5AR2 | FDPS 1189/4885LTA4H 287/4885ALDH1A1 2010/4885 |
| US-20230192708-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | C3AR1, C5AR1, C5AR2 | FDPS 1189/4885LTA4H 287/4885ALDH1A1 2010/4885 |
| US-11608341-B2 | Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators | C5AR1, C3AR1, C5AR2 | FDPS 581/4885LTA4H 393/4885ALDH1A1 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.